<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Corpus uteri: Carcinoma and carcinosarcoma TNM staging AJCC UICC 8th edition</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Corpus uteri: Carcinoma and carcinosarcoma TNM staging AJCC UICC 8th edition</h1>
<div class="graphic"><div class="figure"><div class="ttl">Corpus uteri: Carcinoma and carcinosarcoma TNM staging AJCC UICC 8th edition</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4">The definitions of the T categories correspond to the stages accepted by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO). Both systems are included for comparison.</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Primary tumor (T)</td> </tr> <tr class="divider_bottom"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan="2"><strong>T criteria</strong></td> </tr> <tr> <td class="indent1">TX</td> <td> </td> <td colspan="2">Primary tumor cannot be assessed</td> </tr> <tr> <td class="indent1">T0</td> <td> </td> <td colspan="2">No evidence of primary tumor</td> </tr> <tr> <td class="indent1">T1</td> <td>I</td> <td colspan="2">Tumor confined to the corpus uteri, including endocervical glandular involvement</td> </tr> <tr> <td class="indent2">T1a</td> <td>IA</td> <td colspan="2">Tumor limited to the endometrium or invading less than half the myometrium</td> </tr> <tr> <td class="indent2">T1b</td> <td>IB</td> <td colspan="2">Tumor invading one half or more of the myometrium</td> </tr> <tr> <td class="indent1">T2</td> <td>II</td> <td colspan="2">Tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does NOT include endocervical glandular involvement.</td> </tr> <tr> <td class="indent1">T3</td> <td>III</td> <td colspan="2">Tumor involving serosa, adnexa, vagina, or parametrium</td> </tr> <tr> <td class="indent2">T3a</td> <td>IIIA</td> <td colspan="2">Tumor involving the serosa and/or adnexa (direct extension or metastasis)</td> </tr> <tr> <td class="indent2">T3b</td> <td>IIIB</td> <td colspan="2">Vaginal involvement (direct extension or metastasis) or parametrial involvement</td> </tr> <tr> <td class="indent1">T4</td> <td>IVA</td> <td colspan="2">Tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4)</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4">T suffix (m) if synchronous primary tumors are found in a single organ.</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Regional lymph nodes (N)</td> </tr> <tr class="divider_bottom"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan="2"><strong>N criteria</strong></td> </tr> <tr> <td class="indent1">NX</td> <td> </td> <td colspan="2">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class="indent1">N0</td> <td> </td> <td colspan="2">No regional lymph node metastasis</td> </tr> <tr> <td class="indent1">N0(i+)</td> <td> </td> <td colspan="2">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr> <td class="indent1">N1</td> <td>IIIC1</td> <td colspan="2">Regional lymph node metastasis to pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N1mi</td> <td>IIIC1</td> <td colspan="2">Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N1a</td> <td>IIIC1</td> <td colspan="2">Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes</td> </tr> <tr> <td class="indent1">N2</td> <td>IIIC2</td> <td colspan="2">Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N2mi</td> <td>IIIC2</td> <td colspan="2">Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N2a</td> <td>IIIC2</td> <td colspan="2">Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4"> <p>Suffix (sn) is added to the N category when regional lymph node metastasis is identified by sentinel lymph node biopsy only.</p> Suffix (f) is added to the N category when metastasis is identified by fine needle aspiration (FNA) or core needle biopsy only.</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Distant metastasis (M)</td> </tr> <tr class="divider_bottom"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan="2"><strong>M criteria</strong></td> </tr> <tr> <td class="indent1">cM0</td> <td> </td> <td colspan="2">No distant metastasis</td> </tr> <tr> <td class="indent1">cM1</td> <td>IVB</td> <td colspan="2">Distant metastasis (includes to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone).<br/> (It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa.)</td> </tr> <tr class="divider_bottom"> <td class="indent1">pM1</td> <td>IVB</td> <td colspan="2">Distant metastasis (includes to inguinal lymph nodes, intraperitoneal disease, liver, or bone) microscopically confirmed.<br/> (It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa.)</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Prognostic stage groups</td> </tr> <tr class="divider_bottom"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class="indent1">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class="indent1">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class="indent1">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class="indent1">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class="indent1">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class="indent1">T3a</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class="indent1">T3b</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class="indent1">T1-T3</td> <td>N1/N1mi/N1a</td> <td>M0</td> <td>IIIC1</td> </tr> <tr> <td class="indent1">T1-T3</td> <td>N2/N2mi/N2a</td> <td>M0</td> <td>IIIC2</td> </tr> <tr> <td class="indent1">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr class="divider_bottom"> <td class="indent1">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Histologic grade (G)</td> </tr> <tr class="divider_bottom"> <td><strong>G</strong></td> <td colspan="3"><strong>G definition</strong></td> </tr> <tr> <td class="indent1">GX</td> <td colspan="3">Grade cannot be assessed</td> </tr> <tr> <td class="indent1">G1</td> <td colspan="3">Well differentiated</td> </tr> <tr> <td class="indent1">G2</td> <td colspan="3">Moderately differentiated</td> </tr> <tr class="divider_bottom"> <td class="indent1">G3</td> <td colspan="3">Poorly differentiated</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Histopathology: Degree of differentiation</td> </tr> <tr class="divider_bottom"> <td colspan="4">Cases of carcinoma of the corpus uteri should be grouped according to the degree of differentiation of the endometrioid adenocarcinoma:</td> </tr> <tr class="highlight_gray_text divider_bottom"> <td><strong>G</strong></td> <td colspan="3"><strong>G definition</strong></td> </tr> <tr> <td class="indent1">G1</td> <td colspan="3">5% or less of a nonsquamous or nonmorular solid growth pattern</td> </tr> <tr> <td class="indent1">G2</td> <td colspan="3">6-50% of a nonsquamous or nonmorular solid growth pattern</td> </tr> <tr> <td class="indent1">G3</td> <td colspan="3">More than 50% of a nonsquamous or nonmorular solid growth pattern. Papillary serous, clear cell, and carcinosarcoma are considered high grade.</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4"><em>NOTES on pathologic grading:</em> <ol> <li>Notable nuclear atypia exceeding that which is routinely expected for the architectural grade increases the tumor grade by 1 (ie, 1 to 2 and 2 to 3). </li> <li>Serous, clear cell, and mixed mesodermal tumors are <em>high risk</em> and considered grade 3. </li> <li>Adenocarcinomas with benign squamous elements (squamous metaplasia) are graded according to the nuclear grade of the glandular component. </li> </ol> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Lymphovascular invasion (LVI)</td> </tr> <tr class="divider_bottom"> <td><strong>Component of LVI coding</strong></td> <td colspan="3"><strong>Description</strong></td> </tr> <tr> <td class="indent1">0</td> <td colspan="3">LVI not present (absent)/not identified</td> </tr> <tr> <td class="indent1">1</td> <td colspan="3">LVI present/identified, NOS</td> </tr> <tr> <td class="indent1">2</td> <td colspan="3">Lymphatic and small vessel invasion only (L)</td> </tr> <tr> <td class="indent1">3</td> <td colspan="3">Venous (large vessel) invasion only (V)</td> </tr> <tr> <td class="indent1">4</td> <td colspan="3">BOTH lymphatic and small vessel AND venous (large vessel) invasion</td> </tr> <tr> <td class="indent1">9</td> <td colspan="3">Presence of LVI unknown/indeterminate</td> </tr> </tbody></table></div><div class="graphic_footnotes">TNM: Tumor, Node, Metastasis; NOS: not otherwise specified.</div><div class="graphic_reference">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id="graphicVersion">Graphic 113543 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
